Hyperhomocysteinemia and Cardiovascular Disease: New Mechanisms Beyond Atherosclerosis

Metabolic Syndrome and Related Disorders

Volumn 1, Issue 2, 2003, Pages 97-104

  Joseph, Jacob ^a   Joseph, Lija ^a  

^a CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 2942574018     PISSN: 15404196     EISSN: 15578518     Source Type: Journal    
DOI: 10.1089/154041903322294425     Document Type: Review

References (67)

1. Butz LW, du Vigneaud V. Formation of a homologue of cystine by the decomposition of methionine with sulfuric acid. J Biol Chem 1932; 99: 135–142.
2. Gerritsen T, Vaughn JG, Waisman HA. The identification of homocysteine in the urine. Biochem Biophys Res Commun 1962; 9: 493–496.
3. Carson NA, Neill DW. Metabolic abnormalities detected in a survey of mentally backward individuals in northern Ireland. Arch Dis Child 1962; 37: 505–513.
4. Mudd SH, Finkelstein JD, Irreverre F, et al. Homocystinuria: an enzymatic defect. Science 1964; 143: 1443–1445.
5. Schimke RN, McKusick VA, Huang T, et al. Homocystinuria. Studies of 20 families with 38 affected members. JAMA 1965; 193: 711–719.
6. McCully KS. Vascular pathology of hyperhomocysteinemia: implications for the development of arteriosclerosis. Am J Pathol 1969; 56: 111–128.
7. McCully KS, Wilson BB. Homocysteine theory of atherosclerosis. Atherosclerosis 1975; 22: 215–227.
8. McCully KS. Homocysteine and vascular disease. Nat Med 1996; 2: 386–389.
9. Malinow MR, Duell PB, Hess DL, et al. Reduction of plasma homocysteine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease. N Engl J Med 1998; 338: 1009–1015.
10. Hankey GH, Eikelboom JW. Homocysteine and vascular disease. Lancet 1999; 354: 407–413.
11. Boushey CJ, Beresford SAA, Omenn GS, et al. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intake. JAMA 1995; 274: 1049–1057.
12. Nygard O, Nordrehaug JE, Refsum H, et al. Plasma homocysteine levels and mortlaity in patients with coronary artery disease. N Engl J Med 1997; 337: 230–236.
13. Eikelboom JE, Lonn E, Genest Jr J, et al. Homocysteine and cardiovascular disease. A critical review of the epidemiological evidence. Ann Intern Med 1999; 131:363–375.
14. Schnyder G, Roffi M, Pin R, et al. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med 2001; 345: 1593–1600.
15. 6 on clinical outcome after percutaneous intervention: the Swiss Heart study: a randomized control trial. JAMA 2002; 288: 973–979.
16. Blacher J, Demuth K, Guerin AP, et al. Association between plasma homocysteine concentrations and cardiac hypertrophy in end-stage renal disease. J Nephrol 1999; 12: 248–255.
17. Durand P, Prost M, Loreau N, et al. Impaired homocysteine metabolism and atherothrombotic disease. Lab Jnvest 2001; 81: 645–672.
18. Eberhardt RT, Forgione MA, Cap A, et al. Endothelial dysfunction in a murine model of mild hyperhomocysteinemia. J Clin Jnvest 2000; 106: 483–491.
19. Lentz SR, Sadler JE. Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine. J Clin Invest 1991; 88: 1906–1914.
20. Wang H, Yoshizumi M, Lai K, et al. Inhibition of growth and p21ras methylation in vascular endothelial cells by homocysteine but not cysteine. J Biol Chem 1997; 272: 25380–25385.
21. Harker IA, Ross R, Slichter SJ, et al. Homoystine-induced arterioscelrosis. The role of endothelial cell injury and platelet response in its genesis. J Clin Invest 1976; 58: 731–741.
22. Poddar R, Sivasubramanian N, DiBello PM, et al. Homocysteine induces expression and secretion of monocyte chemoattractant protein-1 and interleukin-8 in human aortic endothelial cells. Implications for vascular disease. Circulation 2001; 103: 2717–2723.
23. Southern FN, Cruz N, Fink LM, et al. Hyperhomocysteinemia increases intimal hyperplasia in a rat carotid endarterectomy model. J Vasc Surg 1998; 28: 908–918.
24. Wang H, Yoshizumi M, Lai K, et al. Inhibition of growth and p21ras methylation in vascular endothelial cells by homocysteine but not cysteine. J Biol Chem 1997; 272: 25380–25385.
25. Outinen PA, Sood SK, Liaw PCY, et al. Characterization of the stress-inducing effects of homocysteine. Biochem J 1998; 332: 213–221.
26. Nonaka H, Tsujino T, Watari Y, et al. Taurine prevents the decrease in expression and secretion of extracellular superoxide dismutase induced by homocysteine. Circulation 2001; 104: 1165–1170.
27. Tsai J-C, Wang H, Perella MA, et al. Induction of cyclin A gene expression by homocysteine in vascular smooth muscle cells. J Clin Invest 1996; 97: 146–153.
28. Tsai J-C, Perella MA, Yoshizumi M, et al. Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci USA 1994; 91: 6369–6373.
29. Dalton ML, Gadson PF, Wrenn RW, et al. Homocysteine signal cascade: production of phospholipids, activation of protein kinase C, and the induction of c-fos and c-myb in smooth muscle cells. FASEB J 1997; 11: 703–711.
30. Mujumdar VS, Hayden MR, Tyagi SC. Homocysteine induces calcium second messenger in vascular smooth muscle cells. J Cell Physiol 2000; 183: 28–36.
31. Carmody BJ, Arora S, Avena R, et al. Folic acid inhibits homocysteine-induced proliferation of human arterial smooth muscle cells. J Vasc Surg 1999; 30: 1121–1128.
32. Majors A, Ehrhart A, Pezacka EH. Homocysteine as a risk factor for vascular disease: enhanced collagen production and accumulation by smooth muscle cells. Arterioscler Thromb Vasc Biol 1997; 17: 2074–2081.
33. Tyagi SC. Homocysteine and heart disease: pathophysiology of extracellular matirx. Clin Exp Hypertens 1999; 21: 181–198.
34. Tyagi SC, Smiley LM, Mujumdar VS, et al. Reduction-oxidation and vascular tissue level of homocysteine in human coronary atherosclerotic lesions and role in extracellular matrix remodeling and vascular tone. Mol Cell Biochem 1998; 181: 107–116.
35. Bescond A, Augier T, Chareyre C, et al. Influence of homocysteine on matrix metalloproteinase-2: activation and activity. Biochem Biophys Res Commun 1999; 263: 498–503.
36. Torres L, Garcia-Trevijano ER, Rodriguez JA, et al. Induction of TIMP-1 expression in rat hepatic stellate cells and hepatocytes: a new role for homocysteine in liver fibrosis. Biochim Biophys Acta 1999; 1455: 12–22.
37. Loscalzo J. The oxidant stress of hyperhomocysteinemia. J Clin Invest 1996; 98: 5–7.
38. Jia L, Firchgott RF. Inhibition by sulphydryl compounds of vascular relaxation induced by nitric oxide and endothelium-derived relaxing factor. J Pharmacol Exp Ther 1993; 267: 371–378.
39. Upchurch GR, Welch GN, Freedman JE, et al. Homocysteine attenuates endothelial glutathione peroxidase and thereby potentiates peroxide-mediated cell injury. Circulation 1995; 92: 1–228.
40. Abdelfatah A, Ducloux D, Toubin G, et al. Treatment of hyperhomocysteinemia with folic acid reduces oxidative stress in renal transplant recipients. Transplantation 2002; 7: 663–665.
41. Tyagi SC. Homocysteine redox receptor and regulation of extracellular matrix components in vascular cells. Am J Physiol 1998; 274: C396-C405.
42. Weiss N, Zhang YY, Heydrick S, et al. Overexpression of cellular glutathione peroxidase rescues homocysteine-induced endothelial dysfunction. Proc Natl Acad Sci USA 2001; 98: 12503–12508.
43. Zheng H, Dimayuga C, Hudaihed A, et al. Effect of dexrazoxane on homocysteine-induced endothelial dysfunction in normal subjects. Arterioscler Thromb Vasc Biol 2002; 22: E15–E18.
44. Guba SC, Fonseca V, Fink LM. Hyperhomocysteinemia and thrombosis. Semin Thromb Hemost 1999; 25: 291–309.
45. Harker LA, Ross R, Slichter SJ, et al. Homocystine-inducd arteriosclerosis. The role of endothelial cell injury and platelet response in its genesis. J Clin Invest 1976; 58: 731–741.
46. Zhang C, Cai Y, Adachi MT, et al. Homocysteine induces programmed cell death in human vascular endothelial cells through activation of the unfolded protein response. J Biol Chem 2001; 276: 35867–35874.
47. Koga T, Claycombe K, Meydani M. Homocysteine increases monocyte and T-cell adhesion to human aortic endothelial cells. Atherosclerosis 2002; 161: 365–374.
48. Ungvari Z, Sarkadi-Nagy E, Bagi Z, et al. Simultaneously increased TxA2 activity in isolated arterioles and platelets of rats with hyperhomocysteinemia. Arterioscler Thromb Vasc Biol 2000; 20: 1203–1208.
49. Harpel P, Zhang X, Borth W. Homocysteine and hemostasis: pathogenic mechanisms predisposing to thrombosis. J Nutr 1996; 126: 1285S–1289S.
50. Lentz SR, Piegors DJ, Fernandez JA, et al. Effect of hyperhomocysteinemia on protein C activation and activity. Blood 2002; 100: 2108–2112.
51. Durand P, Prost M, Blache D. Pro-thrombotic effects of a folic acid deficient diet in rat platelets and macrophages related to elevated homocysteine and decreased n-3 polyunsaturated fatty acids. Atherosclerosis 1996; 121: 231–243.
52. Hajjar K, Mauri L, Jacovina AT, et al. Tissue plasminogen activator binding to the annexin II tail domain. Direct modulation by homocysteine. J Biol Chem 1998; 273: 9987–9993.
53. Lauricella AM, Quintana IL, Kordich LC. Effects of homocysteine thiol group on fibrin networks: another possible mechanism of harm. Thromb Res 2002; 107:75–79.
54. Joseph J, Washington A, Joseph L, et al. Hyperhomocysteinemia leads to adverse cardiac remodeling in hypertensive rats. Am J Physiol 2002; 283: H2567–H2574.
55. Melchert RB, Joseph J, Kennedy RH. Interaction of xenobiotics with myocardial signal transduction pathways. Cardiovasc Toxicol, 2002; 2: 1–23.
56. Chen P, Poddar R, Tipa EV, et al. Homocysteine metabolism in cardiovascular cells and tissues: implications for hyperhomocysteinemia and cardiovascular disease. Adv Enzyme Regul 1999; 39: 93–109.
57. Lakka H-M, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288:2709–2716.
58. Tschoepe D, Roesen P, Scherbaum WA. The heart and metabolic syndrome. Z Kardiol 1999; 88: 215–224.
59. Juhan-Vague I, Alessi MC, Vague P. Thrombogenic and fibrinolytic factors and cardiovascular risk in non-insulin-dependent diabetes mellitus. Ann Med 1996; 28: 371–380.
60. Vague P, Raccah D, Scelles V. Hypofibrinolysis and the insulin resistance syndrome. Int J Obes Relat Metab Disord 1995; 19(Suppl 1):S11–S15.
61. Frolich J, Steiner G. Dyslipidemia and coagulation defects of insulin resistance. Int J Clin Pract Suppl 2000; 113: 14–22.
62. Fujii S, Goto D, Zaman T, et al. Diminished fibrinolysis and thrombosis: clinical implications for accelerated atherosclerosis. J Atheroscler Thromb 1998; 5: 76–81.
63. Watanabe Y, Sunayama S, Shimada K, et al. Troglitazone improves endothelial dysfunction in patients with insulin resistance. J Atheroscler Thromb 2000; 7: 159–163.
64. Meigs JB, Jacques PF, Selhub J, et al. Fasting plasma homocysteine levels in the insulin resistance syndrome: the Framingham offspring study. Diabetes Care 2001; 24: 1403–1410.
65. Hoogeven EK, Kostense PJ, Beks PJ, et al. Hyperhomocysteinemia is associated with an increased risk of cardiovascular disease, especially in non-insulin-dependent diabetes mellitus: a population based study. Arterioscler Thromb Vasc Biol 1998; 18: 133–138.
66. Jager A, Kostense PJ, Nijpels G, et al. Serum homocysteine levels are associated with the development of microalbuminuria: the Hoorn study. Arrterioscler Thromb Vasc Biol 2001; 21: 74–81.
67. Baliga BS, Reynolds T, Fink LM, et al. Hyperhomocysteinemia in type 2 diabetes mellitus: cardiovascular risk factors and effect of treatment with folic acid and pyridoxine. Endocr Pract 2000; 6: 435–441.